THE DUAL-SYSTEM HYPOTHESIS OF ANOSOGNOSIA: The Interplay Between Emotional Processing and Self-Monitoring in Neurodegenerative Patients
NCT06794580 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77
Last updated 2026-02-27
Summary
The ASSESS project is a monocenter, regionally based, study evaluating the pathophysiological/functional processes underlying anosognosia in both AD and bvFTD. The multimodal analysis will be applied to the obtained cognitive, neuroimaging and electrophysiological data in order to describe the mechanistic cascade of anosognosia and their neuronal and electrophysiological biomarkers. Importantly, it has the potential to significantly impact society by: i) addressing a fundamental scientific question towards a causal understanding on how self-awareness emerges in the human brain; and ii) developing a cognitive BCI-system, which will allow us to validated neurophenomenologically EEG biomarkers in anosognosia, and may give us access in later steps to neurofeedback applications for the improvement of self-awareness in early stages of AD and bvFTD, with major social and economic gains.
Conditions
- Anosognosia
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
lead OTHER_GOV
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-22
- Primary Completion
- 2021-11-21
- Completion
- 2021-11-24
Countries
- France
Study Locations
More Related Trials
-
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
NCT05040048 ·Status: COMPLETED
-
Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias
NCT06880406 ·Status: RECRUITING ·Phase: NA
-
48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease
NCT04002583 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease
NCT00888056 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Shanghai At Risk for Alzheimer's Disease: a Cohort Study
NCT05597410 ·Status: RECRUITING
-
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
NCT01024660 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
InRAD Observational Study
NCT07213700 ·Status: RECRUITING
-
Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
NCT01327859 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
NCT06868030 ·Status: NOT_YET_RECRUITING
-
The Evaluation and Follow-up of Individuals With Memory Disorder
NCT00001480 ·Status: COMPLETED
-
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)
NCT02537938 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease
NCT06585384 ·Status: RECRUITING ·Phase: PHASE1
-
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
NCT04699786 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
NCT02788513 ·Status: COMPLETED ·Phase: PHASE2
-
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping
NCT04928690 ·Status: UNKNOWN
-
Models of Disordered Knowledge and Memory Systems in Dementia and Related Disorders
NCT00004557 ·Status: COMPLETED
-
Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients
NCT05383053 ·Status: COMPLETED
-
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
NCT06996730 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352 ·Status: RECRUITING ·Phase: PHASE3
-
Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
NCT05468073 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
NCT01117818 ·Status: COMPLETED ·Phase: PHASE2
-
Cytokines and Cognitive Decline in Alzheimer's Disease
NCT01351142 ·Status: COMPLETED ·Phase: NA
-
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
NCT00880347 ·Status: COMPLETED ·Phase: NA
-
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
NCT02322021 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
NCT04971733 ·Status: COMPLETED ·Phase: PHASE1/PHASE2